AKTS Aktis Oncology, Inc.
Nasdaq · SEC CIK 2035832 · EDGAR
- Bought, last 12 months
- $114.31M 6 purchases by 6 insiders
- Sold, last 12 months
- $3.23M 5 sales by 3 insiders
- Filings on record
- 13 since 2026-01-12, latest 2026-09-24 16:05
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| NODELMAN OLEG | Dir | $40.00M | — |
| MPM ONCOLOGY INNOVATIONS FUND LP | 10% | $20.03M | — |
| GADICKE ANSBERT | 10% | $20.03M | — |
| VIDA VENTURES II-A, LLC | 10% | $15.03M | — |
| Kim Helen Susan | Dir, 10% | $15.03M | — |
| Foley Todd | Dir, 10% | $4.19M | — |
| Czibere Akos | Chief Medical Off | — | $1.65M |
| Ron-Bigger Shulamit | COO | — | $1.39M |
| Herrmann Ken | Dir | — | $196.5K |
| Segal Lloyd Mitchell | Dir | — | — |
Transactions 23
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-24 16:05 | 2026-09-23 | AKTS | Czibere Akos | Chief Medical Off | M - OptEx | $4.95 | +12.5K | 12.5K | New | +$61.9K |
| DMT | 2026-09-24 16:05 | 2026-09-23 | AKTS | Czibere Akos | Chief Medical Off | S - Sale+OE | $20.69 | -12.5K | 0 | -100% | -$258.6K |
| DM | 2026-07-21 20:50 | 2026-07-20 | AKTS | Herrmann Ken | Dir | M - OptEx | $0.5888 | +4,856 | 4,856 | New | +$2,859 |
| DM | 2026-07-21 20:50 | 2026-07-20 | AKTS | Herrmann Ken | Dir | S - Sale+OE | $24.56 | -4,856 | 0 | -100% | -$119.3K |
| D | 2026-07-20 17:34 | 2026-07-17 | AKTS | Herrmann Ken | Dir | M - OptEx | $0.08 | +3,065 | 3,065 | New | +$245.20 |
| D | 2026-07-20 17:34 | 2026-07-17 | AKTS | Herrmann Ken | Dir | S - Sale+OE | $25.21 | -3,065 | 0 | -100% | -$77.3K |
| D | 2026-07-10 06:11 | 2026-07-08 | AKTS | Ron-Bigger Shulamit | COO | M - OptEx | $3.66 | +50.0K | 50.0K | New | +$183.0K |
| DM | 2026-07-10 06:11 | 2026-07-08 | AKTS | Ron-Bigger Shulamit | COO | S - Sale+OE | $27.75 | -50.0K | 0 | -100% | -$1.39M |
| D | 2026-07-10 06:10 | 2026-07-08 | AKTS | Czibere Akos | Chief Medical Off | M - OptEx | $4.95 | +50.0K | 50.0K | New | +$247.5K |
| DM | 2026-07-10 06:10 | 2026-07-08 | AKTS | Czibere Akos | Chief Medical Off | S - Sale+OE | $27.77 | -50.0K | 0 | -100% | -$1.39M |
| DMI | 2026-01-14 | 2026-01-12 | AKTS | MPM ONCOLOGY INNOVATIONS FUND LP | 10% | C - Cnv Deriv | — | +8.81M | 1.66M | New | — |
| DI | 2026-01-14 | 2026-01-12 | AKTS | MPM ONCOLOGY INNOVATIONS FUND LP | 10% | P - Purchase | $18.00 | +1.11M | 10.26M | +12% | +$20.03M |
| DMI | 2026-01-14 | 2026-01-12 | AKTS | GADICKE ANSBERT | 10% | C - Cnv Deriv | — | +8.81M | 7.57M | New | — |
| DI | 2026-01-14 | 2026-01-12 | AKTS | GADICKE ANSBERT | 10% | P - Purchase | $18.00 | +1.11M | 10.26M | +12% | +$20.03M |
| DMI | 2026-01-14 | 2026-01-12 | AKTS | Foley Todd | Dir, 10% | C - Cnv Deriv | — | +4.00M | 4.00M | New | — |
| DI | 2026-01-14 | 2026-01-12 | AKTS | Foley Todd | Dir, 10% | P - Purchase | $18.00 | +232.9K | 4.24M | +6% | +$4.19M |
| DMI | 2026-01-12 | 2026-01-12 | AKTS | VIDA VENTURES II-A, LLC | 10% | C - Cnv Deriv | — | +4.99M | 134.8K | New | — |
| DMI | 2026-01-12 | 2026-01-12 | AKTS | VIDA VENTURES II-A, LLC | 10% | P - Purchase | $18.00 | +835.0K | 5.67M | +17% | +$15.03M |
| DMI | 2026-01-12 | 2026-01-12 | AKTS | NODELMAN OLEG | Dir | P - Purchase | $18.00 | +2.22M | 347.3K | New | +$40.00M |
| DMI | 2026-01-12 | 2026-01-12 | AKTS | NODELMAN OLEG | Dir | C - Cnv Deriv | — | +2.60M | 2.27M | New | — |
| DI | 2026-01-12 | 2026-01-12 | AKTS | Segal Lloyd Mitchell | Dir | C - Cnv Deriv | — | +19.6K | 19.6K | New | — |
| DMI | 2026-01-12 | 2026-01-12 | AKTS | Kim Helen Susan | Dir, 10% | C - Cnv Deriv | — | +4.99M | 134.8K | New | — |
| DMI | 2026-01-12 | 2026-01-12 | AKTS | Kim Helen Susan | Dir, 10% | P - Purchase | $18.00 | +835.0K | 5.67M | +17% | +$15.03M |
Purchase Sale Sale after option exercise All abbreviations